{"url_path":"/sec/goss/8-k/2026-07-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1728117/0001728117-26-000057-index.html","accession_number":"0001728117-26-000057","cik":"0001728117","ticker":"GOSS","issuer_name":"Gossamer Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728117/0001728117-26-000057-index.html","primary_entity_key":"0001728117","primary_entity_name":"Gossamer Bio, Inc."},"word_count":117,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn July 1, 2026, Gossamer Bio, Inc. (“Gossamer” or the “Company”) issued a press release announcing that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “2030 Convertible Notes”) will be 5,347.5936 shares of the Company’s common stock per $1,000 principal amount of the 2030 Convertible Notes, which represents a conversion price of approximately $0.19 per share of common stock, and the initial exercise price of its warrants to purchase shares of common stock (the “Purchase Warrants”) will be $0.34 per whole share of its common stock. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K."}